Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.
Type:
Grant
Filed:
November 6, 2017
Date of Patent:
February 21, 2023
Assignee:
CITY OF HOPE
Inventors:
Samuel Rahbar, James L. Figarola, Christopher Lincoln, David Horne, Rachael Mooney, Monika Polewski, George Somlo, Lixin Yang, Sanjay Awasthi, Sharad Singhal, Jyotasana Singhal
Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
Type:
Grant
Filed:
October 8, 2019
Date of Patent:
February 14, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
Abstract: The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of ?4?3? GABAA receptors over ?1?2?2 GABAA receptors. The invention also provides methods of treating GABAA disorders using such compositions.
Abstract: Nutraceutical compositions and the methods for preventing and/or mitigating veisalgia by the administration thereof. The nutraceutical compositions address the challenged state of the individual and potentiate their ability to be compliant with treatment when the metabolic functions of the liver are overwhelmed as alcohol metabolism depletes hepatic supplies of needed molecules. The methods provide the nutraceutical composition directly to the end organs where alcohol and toxin infused blood is also metabolized and neutralized.
Abstract: Compositions comprising L-arginine and L-citrulline in specific ratios are provided. Use of such compositions for improving sexual function in a healthy human subject are also provided.
Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.
Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Abstract: The present invention relates to methods of treatment of menstrual cycle induced disorders and symptoms with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects suffering from menstrual cycle induced disorders and symptoms. In particular, methods and kits for therapy of menstrual cycle induced disorders and symptoms with 3-MMC for a variety of disorders and/or conditions, including PMS, PMDD and perimenstrual disorders are provided.
Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.
Abstract: Yes-associated protein (Yap), a downstream co-activator of the Hippo pathway, is highly expressed in the Treg cell subset, and is critical to maintain its suppressive activity. Originally discovered in Drosophila melanogaster, the Hippo signaling pathway is a major regulator of cellular growth and proliferation in mammals. Loss of Yap expression in Treg cells can lead to superior anti-tumor immune responses, and thus, Yap is an important immunotherapeutic target for cancer.
Type:
Grant
Filed:
February 12, 2016
Date of Patent:
November 8, 2022
Assignee:
The Johns Hopkins University
Inventors:
Fan Pan, Duojia Pan, Drew M. Pardoll, Joseph Barbi, Benjamin Park
Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.
Type:
Grant
Filed:
April 19, 2019
Date of Patent:
November 1, 2022
Assignee:
Estetra SPRL
Inventors:
Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.
Type:
Grant
Filed:
May 10, 2022
Date of Patent:
October 25, 2022
Inventors:
Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
Abstract: The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.
Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.
Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
Abstract: The invention features compositions and methods that are useful for increasing the level or activity of SLC16A11 in a subject, there by treating or preventing type 2 diabetes in the subject.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
October 18, 2022
Assignees:
THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Eitan Hoch, Suzanne Beth Rosenberg Jacobs, Victor Rusu, Liping Zhao, Jose M. Mercader Bigas
Abstract: Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.
Type:
Grant
Filed:
May 4, 2022
Date of Patent:
October 4, 2022
Assignee:
NeuroDerm, Ltd.
Inventors:
Tal Birnberg, Liat Adar, Itay Perlstein